Anti-ELOVL1

Elongation of very long chain fatty acid-like (ELOVL) proteins 1-6 are members of the ELO family of proteins, which play an important role in tissue-specific biosynthesis of very long chain fatty acids and sphingolipids. The ELOVL proteins act as catalysts in fatty acid elongation reduction and localize to the endoplasmic reticulum (ER). Elongation of very long chain fatty acids protein 1 (ELOVL1), also referred to as Ssc1, is the human homolog of the yeast ELO3 protein. It is expressed in a variety of tissues and at especially high levels in stomach, skin, intestine, kidney and lung. ELOVL1 participates in the elongation of very long chain saturated and monounsaturated fatty acids of up to 26 carbons and may be required for the development of a barrier in epithelial cells and skin. ELOVL1 is also important for the formation of Myelin in the central nervous system. Impaired ELOVL1 activity may be associated with disorders of sphingolipid metabolism. Protein function: Catalyzes the first and rate-limiting reaction of the four that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. Condensing enzyme that exhibits activity toward saturated C18 to C26 acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis. Indirectly inhibits RPE65 via production of VLCFAs. [The UniProt Consortium]